{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:11:20Z","timestamp":1770999080615,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1136\/ard.2004.032276","type":"journal-article","created":{"date-parts":[[2005,2,11]],"date-time":"2005-02-11T18:28:43Z","timestamp":1108146523000},"page":"ii87-ii90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"S2","title":["Psoriasis treatment: current and emerging directed therapies"],"prefix":"10.1016","volume":"64","author":[{"given":"L S","family":"Winterfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Menter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.032276_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","article-title":"Psoriasis\u2014epidemiology and clinical spectrum","volume":"26","author":"Christophers","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.1136\/ard.2004.032276_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/1523-1747.ep12297659","article-title":"Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores","volume":"107","author":"Fleischer","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2004.032276_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2230.1987.tb01844.x","article-title":"Psoriasis\u2014an index of disability","volume":"12","author":"Finlay","year":"1987","journal-title":"Clin Exp Dermatol"},{"key":"10.1136\/ard.2004.032276_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1085-5629(98)80026-6","article-title":"Quality of life assessments in dermatology","volume":"17","author":"Finlay","year":"1998","journal-title":"Semin Cutan Med Surg"},{"key":"10.1136\/ard.2004.032276_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0190-9622(96)90469-7","article-title":"The outcomes movement and new measures of the severity of psoriasis","volume":"34","author":"McKenna","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2710.1998.00181.x","article-title":"Quality of life measures in psoriasis: a critical appraisal of their quality","volume":"23","author":"Ashcroft","year":"1998","journal-title":"J Clin Pharm Ther"},{"key":"10.1136\/ard.2004.032276_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/135910539700200409","article-title":"The physical, psychological, and social impact of psoriasis","volume":"2","author":"Rapp","year":"1997","journal-title":"J Health Psychol"},{"key":"10.1136\/ard.2004.032276_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mjd.2000.106374","article-title":"Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?","volume":"43","author":"Krueger","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib10","first-page":"580","article-title":"Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model","volume":"146","author":"Nickoloff","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1136\/ard.2004.032276_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/379777a0","article-title":"Pulling the trigger on psoriasis","volume":"379","author":"Boehncke","year":"1996","journal-title":"Nature"},{"key":"10.1136\/ard.2004.032276_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/1523-1747.ep12335758","article-title":"T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice","volume":"109","author":"Gilhar","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2004.032276_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0923-1811(97)00077-7","article-title":"Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice","volume":"17","author":"Sugai","year":"1998","journal-title":"J Dermatol Sci"},{"key":"10.1136\/ard.2004.032276_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0923-1811(97)00064-9","article-title":"Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice","volume":"17","author":"Yamamoto","year":"1998","journal-title":"J Dermatol Sci"},{"key":"10.1136\/ard.2004.032276_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJM197909063011015","article-title":"Cyclosporin A for psoriasis","volume":"301","author":"Mueller","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.032276_bib16","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.1986.03380220076026","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1136\/ard.2004.032276_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1749-6632.1991.tb33479.x","article-title":"DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells","volume":"636","author":"Waters","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"10.1136\/ard.2004.032276_bib18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat Med"},{"key":"10.1136\/ard.2004.032276_bib19","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0190-9622(98)70590-0","article-title":"Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial","volume":"38","author":"Bagel","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1523-1747.ep12529841","article-title":"Characterization of mononuclear cell infiltrates in psoriatic lesions","volume":"71","author":"Bjerke","year":"1978","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2004.032276_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00510050","article-title":"Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies","volume":"275","author":"Bos","year":"1983","journal-title":"Arch Dermatol Res"},{"issue":"suppl II","key":"10.1136\/ard.2004.032276_bib22","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1136\/ard.2004.031120","article-title":"Psoriasis pathophysiology: current concepts of pathogenesis","volume":"64","author":"Kreuger","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.032276_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archderm.138.5.657","article-title":"Biologic therapy for psoriasis: the new therapeutic frontier","volume":"138","author":"Singri","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2004.032276_bib24","first-page":"205","article-title":"The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates","volume":"1","author":"Chisholm","year":"1994","journal-title":"Ther Immunol"},{"key":"10.1136\/ard.2004.032276_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.178.1.211","article-title":"Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses","volume":"178","author":"Miller","year":"1993","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2004.032276_bib26","first-page":"159","article-title":"Immunomodulation by LFA3TIP, and LFA-3\/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers","volume":"2","author":"Meier","year":"1995","journal-title":"Ther Immuno"},{"key":"10.1136\/ard.2004.032276_bib27","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.4049\/jimmunol.152.6.2753","article-title":"Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure\/function analysis in vitro and in human CD2 transgenic mice","volume":"152","author":"Majeau","year":"1994","journal-title":"J Immunol"},{"key":"10.1136\/ard.2004.032276_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","article-title":"An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Lebwohl","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2004.032276_bib29","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1002\/art.10543","article-title":"Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis","volume":"46","author":"Kraan","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032276_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/eji.1830210719","article-title":"Remote T cell co-stimulation via LFA-1\/ICAM-1 and CD2\/LFA-3: demonstration with immobilized ligand\/mAb in monocyte-mediated co-stimulation","volume":"21","author":"Van Seventer","year":"1991","journal-title":"Eur J Immunol"},{"key":"10.1136\/ard.2004.032276_bib31","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.4049\/jimmunol.157.11.4986","article-title":"Humanization of an anti-lymphocyte function\u2014associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1","volume":"157","author":"Werther","year":"1996","journal-title":"J Immunol"},{"key":"10.1136\/ard.2004.032276_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1523-1747.2000.00abs-8.x","article-title":"Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking","volume":"115","author":"Krueger","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2004.032276_bib33","unstructured":"Chamian F, Lin S, Novitskaya I, et al. Presence of \u201cinflammatory\u201d dendritic cells in psoriasis vulgaris lesions and modulation by efalizumab (anti-CD11a). Poster presented at the 65th annual meeting of the Society for Investigative Dermatology, 29 April\u20141 May 2004, Providence, RI, USA."},{"key":"10.1136\/ard.2004.032276_bib34","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","article-title":"Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial","volume":"290","author":"Gordon","year":"2003","journal-title":"JAMA"},{"key":"10.1136\/ard.2004.032276_bib35","first-page":"77","article-title":"Generalized pustular psoriasis following withdrawal of efalizumab","volume":"3","author":"Gaylor","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1136\/ard.2004.032276_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1523-1747.ep12371752","article-title":"T cells involved in psoriasis vulgaris belong to the Th1 subset","volume":"102","author":"Schlaak","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2004.032276_bib37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s004030100240","article-title":"Expression of IL-18 in psoriasis","volume":"293","author":"Ohta","year":"2001","journal-title":"Arch Dermatol Res"},{"key":"10.1136\/ard.2004.032276_bib38","unstructured":"Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy in patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. (in press)."},{"key":"10.1136\/ard.2004.032276_bib39","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2004.032276_bib40","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.032276_bib41","unstructured":"Moreland LW, Schiff M, Cohen S, Fleischmann RM, Baumgartner S, Burge D, et al. Safety and efficacy of up to 5 years of etanercept (Enbrel) therapy in rheumatoid arthritis. Presented at the European League Against Rheumatism 12\u201315 June 2002."},{"key":"10.1136\/ard.2004.032276_bib42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"3 Pt II","key":"10.1136\/ard.2004.032276_bib43","article-title":"Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: Preliminary findings from a 12-week dose-ranging trial","volume":"50","author":"Chen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib44","unstructured":"Menter A. Onercept. Presented at the International Psoriasis Society Meeting, June 2003, New York."},{"key":"10.1136\/ard.2004.032276_bib45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0190-9622(88)70163-2","article-title":"Systemic retinoid therapy for psoriasis","volume":"19","author":"Lowe","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib46","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0190-9622(99)70360-9","article-title":"Acitretin: optimal dosing strategies","volume":"41","author":"Ling","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib47","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0190-9622(99)70362-2","article-title":"Acitretin in combination with UVB or PUVA","volume":"41","author":"Lebwohl","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0190-9622(91)70089-K","article-title":"Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone","volume":"24","author":"Lowe","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib49","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1067\/mjd.2001.116347","article-title":"Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib50","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.136.12.1536","article-title":"Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability","volume":"136","author":"Ashcroft","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2004.032276_bib51","unstructured":"Lowe NJ, Lew-Kaya D, Walker PS. Safety of oral tazarotene in nodulocystic acne. Presented at the 62nd annual meeting of the American Academy of Dermatology, 6\u201311 February 2004, Washington DC, poster no. 67."},{"key":"10.1136\/ard.2004.032276_bib52","unstructured":"Walker PS, Gottlieb A, Guenther L, et al. Safety of oral tazarotene in moderate to severe plaque psoriasis. Presented at the 62nd annual meeting of the American Academy of Dermatology, 6\u201311 February 2004, Washington DC, poster no. 595."},{"key":"10.1136\/ard.2004.032276_bib53","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archderm.1970.04000080016003","article-title":"Hydroxyurea. A new treatment for psoriasis","volume":"102","author":"Leavell","year":"1970","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2004.032276_bib54","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/1523-1747.ep12610346","article-title":"Treatment of psoriasis with oral mycophenolic acid","volume":"65","author":"Jones","year":"1975","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2004.032276_bib55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0190-9622(94)70055-9","article-title":"6-Thioguanine treatment of psoriasis: experience in 81 patients","volume":"30","author":"Zackheim","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib56","first-page":"894","article-title":"Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial","volume":"22","author":"Gupta","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.032276_bib57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-4615-4857-7_53","article-title":"Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses","volume":"455","author":"Scerri","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2004.032276_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0190-9622(96)80148-4","article-title":"Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7\u20139, 1994","volume":"34","author":"Menter","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib59","first-page":"471","article-title":"Topical tacrolimus: an effective therapy for facial psoriasis","volume":"13","author":"Yamamoto","year":"2003","journal-title":"Eur J Dermatol"},{"key":"10.1136\/ard.2004.032276_bib60","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/00015550310003791","article-title":"An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion","volume":"83","author":"Mrowietz","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1136\/ard.2004.032276_bib61","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1067\/mjd.2003.169","article-title":"Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas","volume":"48","author":"Freeman","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib62","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1046\/j.1365-2133.1999.02898.x","article-title":"The effects of ultraviolet radiation on the human immune system","volume":"140","author":"Duthie","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard.2004.032276_bib63","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0190-9622(91)70253-X","article-title":"Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study","volume":"25","author":"Tanew","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib64","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2133.1989.tb01354.x","article-title":"Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone","volume":"120","author":"Iest","year":"1989","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard.2004.032276_bib65","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0190-9622(82)70157-4","article-title":"Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis","volume":"7","author":"Paul","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032276_bib66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0190-9622(82)70005-2","article-title":"Combined methotrexate-PUVA therapy in the treatment of psoriasis","volume":"6","author":"Morison","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"suppl II","key":"10.1136\/ard.2004.032276_bib67","doi-asserted-by":"crossref","first-page":"ii83","DOI":"10.1136\/ard.2004.030791","article-title":"Psoriasis treatment: traditional therapy","volume":"64","author":"Lebwohl","year":"2005","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.032276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:03:15Z","timestamp":1736139795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724424229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":67,"alternative-id":["S0003496724424229"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.032276","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis treatment: current and emerging directed therapies","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.032276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}